How Do I Know Whether an Aspergillosis Research Study Is Trustworthy?
Research news can be exciting. A headline may suggest that a new blood test, medicine, supplement or genetic discovery could transform care for aspergillosis. Sometimes it may point towards a real future improvement. But a single study rarely tells us enough to change treatment today.
This guide can help you read research more confidently, ask sensible questions, and separate an interesting early finding from evidence that is ready to influence care.
The most important rule: research can improve understanding, but it should not lead you to start, stop or change treatment without discussing it with your clinical team.
Start with the headline—but do not stop there
News headlines and social-media posts are designed to attract attention. They may simplify a careful scientific finding into a promise of a breakthrough.
When you see a claim, pause and ask:
- Does the headline link to the original study?
- Was the research carried out in people, animals, laboratory cells or computer models?
- Does it involve aspergillosis, or a different condition entirely?
- Does the study show a possible association, or prove that one thing caused another?
- Has the finding been confirmed by other research?
A study can be interesting and well conducted while still being far too early to affect patient care.
What kind of study is it?
Different kinds of research answer different questions. There is no single perfect study type, but some are better suited to guiding treatment decisions than others.
| Study type | What it can tell us | Important limitation |
|---|---|---|
| Laboratory or cell study | How Aspergillus, immune cells or a medicine might behave | Promising results in a laboratory do not always work in people |
| Case report | What happened to one patient or a very small number of patients | It cannot show how common an effect is or prove that a treatment caused the outcome |
| Observational study | Patterns, risk factors and possible links in real groups of people | People differ in many ways, so an association does not automatically prove cause and effect |
| Clinical trial | Whether a treatment appears safe and effective in selected patients | Early trials may be small, short or focused on a particular group |
| Systematic review or guideline | What the whole body of relevant evidence suggests | Its conclusions can only be as strong as the studies available |
For treatment decisions, doctors usually look for a consistent pattern across several studies, alongside clinical experience, safety information and guidance from expert groups.
How many people took part?
Small studies are often an essential first step, particularly in rare diseases such as aspergillosis. However, a result from 10 or 20 people may change when it is tested in larger and more varied groups.
Numbers are not everything. It also matters who was included. A study in people receiving chemotherapy or a lung transplant may not apply directly to someone with ABPA, chronic pulmonary aspergillosis (CPA), asthma or bronchiectasis.
Does the study apply to my situation?
Before assuming that a finding applies to you, look for:
- the form of aspergillosis studied;
- other lung conditions people had, such as asthma, COPD, cystic fibrosis or bronchiectasis;
- whether people were taking antifungals, steroids, biologics or chemotherapy;
- the country and healthcare setting; and
- the outcome measured—symptoms, blood tests, scans, hospital admissions, quality of life or survival.
For example, a test that performs well in a specialist laboratory may not yet be available or reliable enough for routine use everywhere. A treatment that helps one group may not be safe or effective for another.
Be careful with the word “breakthrough”
Research often progresses in small but valuable steps. A new diagnostic method may improve accuracy but still need validation. A drug may show activity against Aspergillus in the laboratory but require years of clinical testing. A genetic finding may help explain why disease develops without becoming a test doctors can use in clinic.
Useful questions include:
- Has this changed any clinical guideline or specialist practice?
- Is it available outside a research study?
- What are the possible harms, costs or uncertainties?
- Have other teams found the same result?
Look for conflicts of interest—but keep them in perspective
Research may be funded by universities, charities, public bodies, the NHS, governments or companies developing a test or medicine. Funding does not automatically make research unreliable, but it is reasonable to check who funded the work and whether the authors describe any relevant interests.
Good research reports explain their methods, funding and limitations openly.
Why one paper should not change your treatment
Most treatments become part of routine care only after several stages of evidence: early laboratory work, clinical studies, independent confirmation, safety monitoring and review by experts. For aspergillosis, treatment choices also need to take account of your diagnosis, scans, symptoms, other medicines, drug interactions and blood-test monitoring.
That is why a specialist may be interested in a new paper without immediately changing anyone’s medication. They are weighing it alongside the wider evidence and your individual circumstances.
A simple checklist
When you see a research story, ask:
- What type of study was it?
- How many people were involved?
- Was it carried out in people with a condition like mine?
- What did it actually measure?
- Does it show an association, or prove a cause?
- Have other studies found the same thing?
- Has it changed clinical guidance or routine practice?
Where can I discuss research I have found?
Bring the paper, headline or link to your next appointment, or ask your specialist nurse, doctor or pharmacist about it. You can also discuss general research topics in our community meetings—but remember that other patients’ experiences can be helpful context, not a substitute for individual medical advice.
For current studies, evidence summaries and emerging developments, visit the Aspergillosis Research Hub. You may also find our guide to using AI safely when you have aspergillosis helpful when you are searching for or interpreting health information online.
Key message
A good research paper can add an important piece to the picture. It is rarely the whole picture on its own. Staying curious is valuable; staying cautious protects you from false hope, unnecessary expense and unsafe treatment changes.
Last reviewed: August 2026. This information is for general education and does not replace advice from your healthcare team.
Finding Extra Support Beyond Aspergillosis: Groups for People with Lung Conditions
Living with aspergillosis can affect far more than the lungs. It can bring fatigue, anxiety, isolation, practical challenges and questions that may not always fit neatly into one support group.
The National Aspergillosis Centre community is a place to meet people who understand aspergillosis. But some people may also find it helpful to explore wider support for asthma, bronchiectasis, pulmonary fibrosis, oxygen use, breathing, gentle activity or emotional wellbeing.
Watch: finding additional respiratory support
In this short clip from the National Aspergillosis Centre’s August 2026 online meeting, Beth explains how wider respiratory-support groups can offer another source of information, encouragement and connection.
Asthma + Lung UK groups and activities
Asthma + Lung UK’s Groups + Support directory brings together local and online support for people with a wide range of lung conditions. It includes support groups, exercise and activity sessions, Singing for Lung Health, and other ways to connect with people who understand the impact of lung disease.
You may find something useful if you have an overlapping condition, such as asthma or bronchiectasis, or if you would simply like to meet people facing similar challenges. Some groups are based locally, while others are online.
There is no need to choose between support communities. The NAC community can remain your aspergillosis-focused home, while another group may offer something different that is helpful to you.
Finding the right kind of support
Different people want different things from a group. You might be looking for practical information, a social conversation, gentle activity, help with confidence after a diagnosis, or simply the reassurance of knowing you are not alone.
It is fine to try a group and decide that it is not for you. Finding the right support can take time, and your needs may change as your health changes.
Support from the National Aspergillosis Centre
Our online meetings and community spaces are designed for people affected by aspergillosis, their carers and families. They offer a chance to share experiences, hear useful information and stay connected.
Find support and community information from the National Aspergillosis Centre
Find out about upcoming NAC online meetings
Watch more: Explore recordings from NAC online meetings for patients, carers and families on YouTube.
This article provides general information and does not replace advice from your own clinical team.
The Future of Aspergillosis Care: Earlier Diagnosis, New Treatments and Personalised Support
Aspergillosis care is changing. Better tests, new medicines, improved monitoring and more careful use of health data may help clinicians diagnose disease earlier and make care more personal in the years ahead.
These short clips come from the National Aspergillosis Centre’s July 2026 online meeting. They are designed for people living with aspergillosis, their carers and families, and anyone wanting to understand more about how care may develop.
There are important reasons for optimism, but progress takes time. New tests and treatments need careful research, and decisions about diagnosis and treatment should always be made with an individual’s own clinical team.
The next 10 years: a more personal future for aspergillosis care
Care is increasingly moving away from a one-size-fits-all approach. In future, diagnosis, monitoring and treatment may be better tailored to the type of aspergillosis a person has, their other health conditions, how their illness affects daily life, and what matters most to them.
In this short video, we explore what a more personal future for aspergillosis care could look like.
The future of treating aspergillosis
Current antifungal medicines remain extremely important, but treatment can be difficult because people respond differently and medicines can have side effects or interactions with other drugs. Research is continuing into new antifungal treatments, better ways to monitor treatment safely, and ways of choosing the most suitable option for each person.
Artificial intelligence and other digital tools may also help clinicians bring together complex information and support more personalised decisions. They are not a replacement for clinical expertise or shared decision-making.
In this short video, we look at how future treatments may offer more options and more personalised care.
The future of diagnosing aspergillosis
Diagnosing aspergillosis is not always straightforward. Symptoms can overlap with asthma, bronchiectasis, COPD and other lung conditions, while different forms of aspergillosis need different tests and treatments.
Future diagnosis may become earlier and more accurate through improved laboratory tests, better interpretation of imaging and blood results, and a fuller picture of each person’s symptoms, lung health and medical history. Earlier recognition matters because it can help people reach the right specialist support sooner.
In this short video, we explore how diagnosis could become earlier, more accurate and more personal.
What this means for patients
The future of care is not only about technology or new medicines. It is also about listening carefully to patients, recognising the impact of long-term illness, and making sure that diagnosis, treatment and support are shaped around the individual.
If you have questions about your own symptoms, tests or treatment, speak to your respiratory, infectious diseases or specialist clinical team. You can also find more patient information and support at Aspergillosis.org.
Watch more: Explore our series of NAC online meetings for patients, carers and families on YouTube.
These videos provide general information for patients, carers, families and anyone wishing to understand more. They do not replace medical advice from your own clinical team.
Electric Fans in Hot Weather: Helpful or Harmful?
As temperatures rise across the UK, many people reach for an electric fan to stay cool. However, you may have seen advice suggesting that fans should be used with caution during very hot weather. Why is that, and what does it mean for people living with aspergillosis and other chronic lung conditions?
Key points
- Electric fans can help most people stay comfortable during UK heatwaves.
- Fans cool the body by increasing the evaporation of sweat.
- In extreme heat, above about 35°C, fans may become less effective for some people.
- Hydration remains one of the most important ways to protect yourself during hot weather.
- People with chronic lung conditions should pay particular attention to avoiding dehydration, which can make mucus thicker and harder to clear.
How do electric fans cool us?
Electric fans do not lower the temperature of the air. Instead, they move air across the skin, helping sweat evaporate more quickly. Because evaporation removes heat from the body, this can make you feel cooler and more comfortable.
For most people, particularly during typical UK summer temperatures, fans are a useful and inexpensive way to reduce discomfort during hot weather.
Why is there advice to limit fan use in extreme heat?
Some public health guidance advises caution when temperatures rise above about 35°C. At these temperatures, a fan may simply blow very hot air across the body. If a person is unable to sweat effectively because of age, illness, dehydration or certain medicines, the cooling benefit may be reduced.
This concern led organisations such as the NHS, UK Health Security Agency (UKHSA) and World Health Organization (WHO) to recommend that fans should not be relied upon as the only cooling strategy during extreme heat.
However, research over the last few years has shown that the situation is more complicated than a simple temperature cut-off. Factors such as humidity, hydration, age and overall health all influence whether a fan is helpful.
What does the research say?
Recent studies suggest that electric fans may still provide benefits for many people, even when temperatures exceed 35°C, particularly if humidity levels are high and the body is able to sweat normally.
Researchers now recognise that there is no single temperature at which fans suddenly become harmful. Instead, their effectiveness depends on the balance between heat gained from the surrounding air and heat lost through sweat evaporation.
The overall message from researchers and public health organisations is that fans remain useful for many people but should be combined with other cooling measures such as drinking fluids, seeking shade and cooling the skin with water.
What does this mean for people with aspergillosis?
For people living with aspergillosis, asthma, chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA) or bronchiectasis, a fan is generally safe and may improve comfort during hot weather.
The greater concern is often dehydration. Hot weather can lead to fluid loss through sweating, which may cause mucus and sputum to become thicker and more difficult to clear from the lungs. This can increase coughing, breathlessness and discomfort.
If you use a fan during hot weather:
- Drink water regularly throughout the day.
- Keep curtains or blinds closed on sun-facing windows.
- Open windows when outdoor temperatures are cooler, particularly overnight.
- Use cool showers, damp cloths or a spray bottle to cool the skin.
- Avoid strenuous activity during the hottest part of the day.
- Continue any airway-clearance techniques recommended by your healthcare team.
Video: keeping cool, safe and well during a heatwave
In this short clip from a National Aspergillosis Centre online meeting, we discuss practical ways to stay cooler, safer and well during a heatwave. It is designed for people living with aspergillosis, their carers and families.
Watch for signs of heat exhaustion
Seek medical advice if you experience:
- Dizziness or fainting
- Severe headache
- Nausea or vomiting
- Excessive tiredness or weakness
- Confusion or difficulty concentrating
- Worsening breathlessness
The bottom line
For most people in the UK, electric fans remain a helpful way to stay comfortable during hot weather. Current evidence suggests that fans are generally beneficial during typical UK heatwaves, especially when used alongside other cooling measures.
The most important message for people with chronic lung conditions is to stay hydrated. Fans can help you feel cooler, but drinking enough fluids, avoiding overheating and recognising the signs of heat-related illness are equally important.
Further reading
- World Health Organization (WHO): Heatwaves – How to Stay Cool
- UK Health Security Agency (UKHSA): Beat the Heat – Staying Safe in Hot Weather
- NHS: Heatwave – How to Cope in Hot Weather
- Meade RD et al. A Critical Review of the Effectiveness of Electric Fans as a Cooling Intervention During Heatwaves. The Lancet Planetary Health (2024)
- Morris NB et al. Electric Fan Use for Cooling During Hot Weather. The Lancet Planetary Health (2021)
Watch more: Explore our series of NAC online meetings for patients, carers and families on YouTube.
Author: National Aspergillosis Centre Team
Reviewed: August 2026
Next review: August 2027
This article is intended for educational purposes and should not replace advice from your healthcare team.
Is a vaccine for chronic pulmonary aspergillosis (CPA) being developed?
Patients sometimes ask whether there is progress towards a vaccine for aspergillosis, and whether it could help people with chronic pulmonary aspergillosis (CPA).
The short answer is: research is continuing, but there is not yet a vaccine available for CPA or any other form of aspergillosis. In fact, there is currently no licensed vaccine for any human fungal infection.
Why has this taken so long?
Scientists have been investigating vaccines against Aspergillus fumigatus for more than 20 years. Early studies showed that several experimental vaccines could help protect mice from severe invasive aspergillosis. Some were based on individual fungal proteins; others used immune cells or parts of the fungal cell wall to train the immune system.
However, a result in mice is only the beginning. A vaccine has to be made consistently, shown to be safe, and then tested in people. This is particularly challenging for aspergillosis because people at greatest risk of severe invasive infection—such as people having chemotherapy or a transplant—may have an immune system that cannot respond strongly to vaccination.
Which forms of aspergillosis are vaccine researchers concentrating on?
Most vaccine research has focused on preventing invasive aspergillosis: the rapidly developing infection that can affect people with severely weakened immune systems. It has the strongest scientific case for prevention, because it can be life-threatening and is often linked to a known period of risk, such as chemotherapy or transplantation.
However, this also creates the central difficulty: people at greatest risk may be least able to produce a strong and lasting response to a vaccine. There is no vaccine for invasive aspergillosis close to routine clinical use.
The chronic and allergic forms of aspergillosis bring further challenges. In allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fungal sensitisation and allergic fungal sinusitis, any approach that stimulates immunity against Aspergillus would have to avoid increasing allergy, IgE responses or harmful inflammation. For aspergillus bronchitis and bronchiectasis, there is not currently a specific vaccine pathway; better diagnosis, airway clearance and antifungal treatment remain the more immediate priorities.
What about CPA?
CPA is different again. It is a long-term infection which usually develops in lungs already affected by conditions such as COPD, previous tuberculosis, bronchiectasis, non-tuberculous mycobacterial infection or previous lung surgery. The relationship between the fungus, the damaged lung and the immune system is complex.
A future vaccine might potentially reduce the risk of infection in some people, but it would not repair the damaged lung that makes CPA possible. There is no vaccine currently in clinical development that is expected to treat established CPA. Treatment continues to rely on careful diagnosis, antifungal medicines when appropriate, monitoring, management of the underlying lung condition, and sometimes surgery or other procedures.
Is there any reason for optimism?
Yes—but it is realistic, long-term optimism. Newer vaccine work is looking at better ways to stimulate the T-cell part of the immune system, which is important in protection against fungi. Researchers are also exploring “pan-fungal” vaccines, designed to protect against more than one serious fungal infection, including Aspergillus.
A vaccine that could help protect against several fungi may be more attractive to fund and develop than one aimed at a single infection. This is a potentially important direction for the field, but it remains early-stage research rather than a treatment likely to reach CPA clinics soon.
For people with CPA, the nearer-term progress is more likely to come from improved diagnosis, new antifungal drugs, better use of existing medicines, therapeutic drug monitoring and research into how the immune response can be supported safely.
Further reading
- 2006 study: an experimental Aspergillus vaccine protected mice from invasive aspergillosis
- 2012 research on the immune mechanisms involved
- 2025 review of progress and challenges in fungal vaccine development
This information is for general education and is not a substitute for individual medical advice. If you have CPA, discuss questions about your treatment or future options with your specialist team.
Help shape the UK’s first laboratory standard for fungal respiratory infections
This consultation is for laboratory and healthcare professionals. It is not intended for patients or members of the public to complete.
For people living with, or at risk of, fungal lung disease, getting the right diagnosis can take time. Symptoms may overlap with other respiratory conditions, and the answer can depend on how a respiratory sample is investigated in the laboratory.
A new proposed UK laboratory standard aims to help make that process more consistent. UK SMI B63, Investigation of samples for lower respiratory tract infections caused by fungal pathogens, is the first UK Standard for Microbiology Investigation dedicated specifically to fungal pathogens in lower respiratory tract samples.
It covers the practical pathway from sample to result: choosing and processing appropriate respiratory samples, and using laboratory approaches such as microscopy, culture and molecular testing, including PCR.
Better and more consistent investigation cannot guarantee an immediate diagnosis or the right treatment for every person. However, it can help laboratories recognise clinically important fungi, report results in a useful way, and give clinical teams better information on which to base treatment decisions.
This is especially important for conditions such as aspergillosis, where delayed recognition can mean prolonged symptoms, uncertainty and repeated courses of treatment that may not address the underlying problem.
The public consultation is an opportunity for laboratory scientists, microbiologists, mycologists, respiratory clinicians, infectious-disease clinicians and other relevant professionals to help make sure the final standard is practical and reflects real NHS laboratory and clinical services.
The consultation closes on 1 September 2026.
Beyond antifungal drugs: could antibodies help the immune system fight Aspergillus?
Most treatments for aspergillosis work by attacking the fungus directly. But researchers are exploring another possibility: helping the immune system recognise and attack the fungus more effectively.
One particularly interesting approach presented at the Fungal Update: Mycology Conference 2026 involves laboratory-made human antibodies designed to recognise proteins in the fungal cell wall.
The work is still at a preclinical stage — it has not yet been tested as a treatment for aspergillosis in people — but it points towards a potentially very different way of treating serious fungal infections.
What are monoclonal antibodies?
Antibodies are proteins made by our immune system. They recognise particular molecular structures, allowing the immune system to identify potential threats.
A monoclonal antibody, or mAb, is an antibody produced specifically to recognise a chosen target.
Monoclonal antibody medicines are already widely used in medicine. Some people with severe asthma, for example, receive biologic treatments based on monoclonal antibodies.
Researchers are now investigating whether the same basic technology could be used against fungi.
Instead of targeting part of the human immune system, these experimental antibodies are designed to recognise structures on the fungus itself.
Are antibodies already used against infections?
Yes. Although using monoclonal antibodies against fungal infections is experimental, the broader idea of using laboratory-made antibodies to prevent or treat infection is already well established.
For example, monoclonal antibodies are used to protect babies and young children against respiratory syncytial virus (RSV). Other antibody treatments have been developed for serious infections including Ebola, HIV and anthrax.
There are also examples of antibodies being used alongside conventional antimicrobial treatment. Bezlotoxumab, for example, targets a toxin produced by Clostridioides difficile and has been used with antibiotics to reduce the risk of recurrent infection.
These treatments work in different ways. Some antibodies block a virus from entering human cells, while others neutralise toxins or interfere with another important part of the infectious process.
The experimental fungal antibodies described at the Fungal Update conference use another strategy. They bind proteins on the fungal cell wall and appear to make the fungus easier for macrophages to recognise and engulf. The researchers also found that this effect was stronger in the presence of antifungal drugs.
So the new idea is not that antibodies can be used against infectious diseases — we already know that they can. The important question is whether this established medical technology can be successfully extended to infections caused by fungi such as Aspergillus.
Targeting the fungal cell wall
At the Fungal Update conference in London in March 2026, Professor Carol Munro of the University of Aberdeen presented preclinical research into human monoclonal antibodies targeting two fungal cell-wall proteins called Utr2 and Pga31.
The researchers are interested in developing a pan-fungal treatment — one potentially capable of recognising more than one important fungal pathogen.
According to the conference report published in The Lancet Microbe, the antibodies bound to both Candida species and Aspergillus fumigatus, including drug-resistant species.
That is particularly interesting because antifungal resistance is an increasing concern. If an antibody attacks a completely different fungal target from conventional antifungal medicines, existing resistance mechanisms might not necessarily prevent it from working.
However, considerably more research will be needed to establish whether that potential translates into an effective treatment.
Helping immune cells recognise the fungus
Binding to the fungus is only part of the story.
The antibodies also increased phagocytosis by macrophages.
Macrophages are immune cells capable of recognising, engulfing and destroying microorganisms and other foreign material.
One way of thinking about an antibody is therefore as a highly specific biological marker. By attaching to its target on a fungus, it can potentially make that fungus easier for immune cells to recognise and attack.
This is fundamentally different from simply giving another conventional antifungal drug.
Antibodies and antifungal drugs might work together
Perhaps one of the most intriguing observations reported at the conference was that antibody binding and macrophage phagocytosis were enhanced in the presence of antifungal drugs.
That raises an interesting possibility.
Future antibody treatments might not necessarily replace drugs such as azoles or echinocandins. Instead, they could potentially be used alongside antifungal treatment, attacking the infection through complementary mechanisms.
The antifungal drug could interfere directly with fungal growth or survival while the antibody helps the immune system recognise and remove the fungus.
Whether this combination would provide a meaningful clinical advantage in aspergillosis remains to be established.
What has actually been demonstrated so far?
This distinction is important.
The experiments reported for Aspergillus fumigatus showed that the antibodies could bind the fungus and enhance its phagocytosis by immune cells.
The striking survival results presented at the conference came from mouse models of Candida infection, not Aspergillus infection.
In immunocompetent mice with disseminated candidiasis, monoclonal antibody treatment was associated with an 83% improvement in survival, together with reductions in fungal burden and kidney lesions.
Researchers also studied immunosuppressed mice with Candida albicans candidaemia. Survival increased from 40% with caspofungin alone to 80% when monoclonal antibodies were added.
Those are encouraging preclinical results, particularly because serious fungal infections often occur in people whose immune systems are weakened.
But they should not be interpreted as evidence that the antibody treatment has already been shown to cure invasive aspergillosis.
Why might antibodies be useful?
Existing antifungal medicines can be highly effective, but treating serious fungal infections presents several difficulties.
One of the attractions of antibody-based treatment is the possibility of attacking fungi through a completely different biological mechanism.
Professor Munro hopes that these potential treatments could also offer advantages such as improved safety, a longer half-life and fewer drug–drug interactions compared with existing small-molecule antifungal drugs.
These remain hoped-for advantages rather than demonstrated benefits in patients.
Nevertheless, they are particularly interesting in fungal disease because people requiring long courses of antifungal treatment can encounter toxicity, interactions with other medicines and difficulties maintaining appropriate drug concentrations.
Treating the fungus — or helping the host?
The antibody research also fits into a wider shift in thinking about fungal treatment.
At the same conference, Professor Frank van de Veerdonk described a phase 3 trial investigating interferon-gamma immunotherapy for candidaemia. The trial had completed enrolment, with the conference report stating that interim results showed no safety signal.
Interferon-gamma and monoclonal antibodies are very different approaches, but they illustrate the same broader idea: treating a fungal infection might involve not only attacking the fungus directly but also using or modifying the patient's immune response.
This is known as host-directed therapy or immunotherapy.
For infections such as aspergillosis, where the interaction between the fungus and the patient's immune system is central to whether disease develops, this is an important area of research.
What happens next?
The monoclonal antibodies described at the conference remain preclinical experimental treatments.
Before a new antibody therapy could become available to patients, researchers would need to establish its safety, determine an appropriate dose, investigate how it behaves in the human body and then test whether it actually improves outcomes in people with fungal infections.
Many treatments that look promising in laboratory and animal experiments do not ultimately succeed in human clinical trials.
Professor Munro nevertheless hopes that these antibodies can progress to clinical testing.
A different direction for antifungal treatment
The antifungal development pipeline is already beginning to expand, including new antifungal drugs designed to attack fungal cells in different ways.
Monoclonal antibodies represent something different again.
Rather than developing another version of an existing antifungal, researchers are exploring whether highly targeted biological treatments could mark fungi for attack by the immune system and work alongside conventional antifungal medicines.
For Aspergillus, the evidence is still at an early stage. The antibodies have been shown to recognise A. fumigatus and enhance its uptake by immune cells in laboratory experiments, but the survival benefits reported so far come from Candida models.
That distinction matters.
But if future studies demonstrate similar effects against Aspergillus in living organisms and eventually in people, monoclonal antibodies could open an entirely new avenue for treating fungal disease.
Research source
Dalla Vecchia E. The Fungal Update: Mycology Conference 2026. The Lancet Microbe. Published online 7 May 2026; 7:101437.
Read The Lancet Microbe conference report
This article discusses early-stage research and does not describe a treatment currently available for aspergillosis. Patients should not change their antifungal treatment without discussing it with their clinical team.
New aspergillosis research update: urine testing, CPA antibodies and choosing antifungal treatment
Research published this week highlights three different parts of aspergillosis care: a possible future urine test for invasive aspergillosis, a detailed review of antibody testing in chronic pulmonary aspergillosis (CPA), and new real-world evidence about the use of three important azole antifungal drugs.
These studies do not immediately change how patients should be diagnosed or treated, but they show how researchers are trying to make diagnosis easier and treatment more individualised.
Could invasive aspergillosis eventually be detected using a urine test?
Diagnosing invasive aspergillosis (IA) can be difficult. It usually occurs in people who are seriously ill or whose immune systems are weakened, and obtaining samples directly from the lungs is not always straightforward.
Researchers have been developing a test called MycoMEIA–Aspergillus, which looks in urine for galactofuranose-containing antigens associated with extracellular vesicles released by Aspergillus.
Extracellular vesicles are tiny membrane-bound packages released by cells, including fungi. Material associated with these vesicles can enter the circulation and ultimately appear in urine, potentially providing a much easier sample in which to look for evidence of infection.
In the new study, researchers examined 920 urine samples from 310 people being investigated for invasive fungal disease.
At the patient level, the test achieved approximately:
- 91% sensitivity — the proportion of people with invasive aspergillosis correctly identified by the test.
- 89% specificity — the proportion without invasive aspergillosis correctly identified as negative.
The overall diagnostic performance was also high, with an area under the receiver operating characteristic curve (AUC) of approximately 0.97.
These are encouraging results, particularly because collecting urine is considerably easier and less invasive than obtaining many respiratory samples.
Does this mean a urine test for aspergillosis is now available?
No.
This is still a developing diagnostic test. The researchers themselves emphasise the need for further confirmation and validation of the final assay before it could become part of routine clinical practice.
The idea also has a longer research history. Earlier studies explored detecting Aspergillus antigens in urine, so the important development here is the strengthening and refinement of this approach rather than the first discovery that Aspergillus-associated material can be detected in urine.
If successfully validated, a urine test could eventually complement existing diagnostic methods rather than necessarily replace them.
Research paper:
Datta K, Baburina I, Zhang SX, et al. Detection of Galactofuranose-Containing Antigens Associated With Aspergillus Extracellular Vesicles in Urine: The Biological Basis of a New Diagnostic for Aspergillosis. Journal of Infectious Diseases. 2026.
Read the research paper
Understanding Aspergillus antibody tests in chronic pulmonary aspergillosis
A second new publication examines a test that is already extremely important in clinical practice: Aspergillus antibody testing in chronic pulmonary aspergillosis (CPA).
CPA is a long-term lung infection caused by Aspergillus, usually developing in people who already have structural lung damage or another underlying lung condition.
Blood tests measuring antibodies against Aspergillus — often reported as Aspergillus IgG — form an important part of CPA diagnosis.
However, interpreting these tests is more complicated than simply deciding whether a result is positive or negative.
The new narrative review examines the different methods used to detect anti-Aspergillus antibodies, their diagnostic performance and some of the difficulties involved in interpreting results.
Why can't an antibody result diagnose CPA on its own?
An antibody response tells doctors that the immune system has recognised Aspergillus. It does not, by itself, prove that the fungus is causing CPA.
Doctors therefore combine several pieces of information, which can include:
- symptoms and how long they have been present;
- CT or other radiological findings;
- Aspergillus IgG or other antibody results;
- fungal culture, PCR or other microbiological evidence where available;
- the patient's underlying lung disease;
- and whether another condition could better explain the findings.
Similarly, an antibody result that is not raised does not necessarily exclude CPA in every patient.
This is why CPA diagnosis is best thought of as assembling several pieces of evidence, rather than relying on a single blood test.
The review is particularly useful because different laboratories and commercial assays can use different techniques and thresholds. Understanding those differences matters when interpreting results and comparing measurements made at different centres.
Research paper:
Gibert C, Maitre T, Godet C, et al. Ins and outs of anti-Aspergillus serology in chronic pulmonary aspergillosis: a narrative review. Clinical Microbiology and Infection. 2026.
Read the research paper
Voriconazole, posaconazole or isavuconazole for invasive pulmonary aspergillosis?
The third study looks at treatment rather than diagnosis.
Researchers used a large global real-world database to investigate how three important triazole antifungal drugs are being used in invasive pulmonary aspergillosis (IPA):
voriconazole, posaconazole and isavuconazole.
Voriconazole has historically had a particularly important role in the treatment of invasive aspergillosis, but clinicians now have several azole options.
That does not mean there is one universally "best" antifungal.
Choice of treatment can depend upon factors including:
- the type and severity of infection;
- other medicines being taken and possible drug interactions;
- liver function;
- previous antifungal exposure;
- adverse effects;
- the susceptibility of the Aspergillus isolate, where this is known;
- whether adequate drug concentrations can be achieved;
- and the individual patient's underlying illnesses.
Real-world database studies are valuable because they show how medicines perform and are selected outside the tightly controlled environment of a clinical trial.
However, they also need careful interpretation. Patients receiving different antifungals may differ substantially in their underlying illnesses and previous treatments, so differences in outcomes cannot automatically be attributed to the antifungal drug itself.
The study therefore contributes to the growing evidence supporting a more individualised approach to antifungal treatment, rather than providing a simple league table of the three medicines.
Research paper:
Hashimoto E, Yoshida S, Kitano T. Clinical positioning of Voriconazole, Posaconazole, and Isavuconazole in the treatment of Invasive Pulmonary Aspergillosis: A Global Real-World Database Study. Journal of Global Antimicrobial Resistance. 2026.
Read the research paper
What does this research mean for patients?
None of these studies means that patients should change their treatment or that current diagnostic tests have suddenly become obsolete.
Instead, together they illustrate three areas in which aspergillosis care continues to develop.
Researchers are looking for simpler samples, such as urine, that might help diagnose serious Aspergillus infections. At the same time, they are improving our understanding of established tests such as Aspergillus IgG and investigating how existing antifungal drugs can be selected more effectively for individual patients.
For people living with aspergillosis, this gradual accumulation of evidence is important. Improvements in diagnosis and treatment often come not from a single dramatic breakthrough, but from many studies that progressively make tests more accurate, treatment choices better informed and care more personalised.
This article discusses newly published research and is intended for general information. New research findings do not automatically represent current clinical guidance. Patients should discuss questions about their diagnosis or antifungal treatment with their clinical team.
Clean Air and Lung Health
Media description:
Illustration accompanying the Clean Air and Lung Health guide, showing indoor and outdoor sources of airborne particles and practical measures including ventilation, moisture control, reducing indoor pollutants, air filtration and choosing lower-pollution routes outdoors.
I’d keep “clean air and lung health” in the filename, title and alt text because it matches the article's focus keyphrase, while the rest describes what is actually visible in the image.
Last reviewed: 17 August 2026
Key points
- Air quality can affect breathing symptoms, particularly in people with asthma, bronchiectasis, COPD and other chronic lung conditions.
- Important pollutants include fine particles, traffic and combustion gases, tobacco smoke, household chemicals, damp, mould and airborne allergens.
- People with aspergillosis do not need completely sterile or fungus-free air — that is neither realistic nor necessary.
- The most useful approach is usually to reduce important sources of pollution, control damp and moisture, ventilate appropriately and reduce exposure when outdoor air quality is poor.
- Air cleaners can sometimes help with airborne particles, but they do not fix damp, mould growth or the source of indoor pollution.
Why does clean air matter?
Every day we breathe thousands of litres of air into our lungs. Along with oxygen, that air contains particles, gases, allergens, fungal spores and other biological material.
For most people, ordinary environmental exposure causes no obvious problem. However, people with chronic respiratory conditions may be more sensitive to changes in air quality. Poor air quality can irritate the airways, increase inflammation and contribute to symptoms such as coughing, wheezing, chest tightness or breathlessness.
This is particularly relevant to people living with conditions such as asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD) and aspergillosis.
Clean air does not mean air completely free from particles or microorganisms. The aim is to reduce avoidable exposure to pollutants and excessive concentrations of substances that may aggravate respiratory disease.
Indoor and outdoor air are connected
We often think of indoor and outdoor air pollution as separate problems, but they interact.
Outdoor pollutants enter buildings through doors, windows, ventilation systems and gaps in the building. At the same time, everyday activities inside the home can create additional pollutants.
Indoor sources can include:
- cooking, particularly combustion and frying
- gas appliances
- wood burners and open fires
- tobacco smoke
- candles and incense
- cleaning sprays and aerosols
- air fresheners and fragranced products
- paints, solvents and some furnishings
- damp and mould growth
NICE identifies people with existing respiratory conditions as particularly vulnerable to poor indoor air quality and advises reducing pollutant sources and using appropriate ventilation.
See the NICE guidance on indoor air quality at home.
Particulate matter
Particulate matter (PM) consists of tiny solid particles and liquid droplets suspended in the air.
You may see references to PM10 and PM2.5. The number refers approximately to the maximum diameter of the particles in micrometres. PM2.5 is particularly important because these very small particles can penetrate deep into the lungs.
Sources include:
- road traffic
- industrial emissions
- wood and solid-fuel burning
- wildfires
- cooking
- smoking
- candles and other combustion
People with existing lung disease may notice increased respiratory symptoms during periods of poor outdoor air quality.
For practical advice about pollution forecasts, air-quality indices and reducing exposure, see our Outdoor Air Pollution and Aspergillosis guide.
Damp, mould and fungal spores
Fungi are a natural part of our environment. Fungal spores are present in outdoor and indoor air, and completely avoiding them is impossible.
Problems are more likely when buildings develop persistent damp or visible mould growth. Moisture allows fungi to grow on walls, ceilings, furnishings and other materials, potentially increasing exposure to fungal spores and fragments.
Damp housing is also associated with respiratory symptoms independently of any single fungal species.
For people with aspergillosis, the sensible objective is therefore not to attempt to eliminate every fungal spore. It is to avoid unusually high or prolonged exposure and to deal with significant damp and mould growth.
NICE recommends tackling the source of damp, repairing water damage, controlling condensation and ensuring appropriate ventilation rather than simply treating visible mould as a surface-cleaning problem.
What about Aspergillus outdoors?
Aspergillus spores are naturally present in the environment. Other fungi, including Cladosporium and Alternaria, can also contribute substantially to airborne fungal-spore levels.
Spore concentrations vary with season, weather, vegetation and local environmental conditions.
A 2026 systematic review of airborne fungal spores found evidence linking higher fungal-spore concentrations with respiratory symptoms in sensitised populations, although relatively few studies directly linked environmental measurements with health outcomes. Read the systematic review.
This does not mean that every increase in outdoor fungal spores causes aspergillosis. Different Aspergillus-related diseases arise from a combination of exposure, underlying lung disease, immune responses and other individual risk factors.
Ventilation: useful, but context matters
Ventilation helps remove moisture and pollutants generated inside a building.
Useful measures can include:
- using kitchen extractor fans while cooking
- using bathroom extraction during and after bathing or showering
- keeping trickle vents open where appropriate
- opening windows when conditions allow
- avoiding prolonged indoor drying of wet clothes without adequate ventilation
However, simply saying “open the windows” is not always good advice.
If outdoor pollution is temporarily high — for example because of heavy traffic, smoke or a pollution episode — opening windows may increase indoor pollution. Buildings beside busy roads may also require a different ventilation strategy from homes in cleaner locations.
The objective is therefore appropriate ventilation, not maximum ventilation at all times.
Cooking and combustion
Cooking can produce substantial amounts of particulate matter, particularly frying and high-temperature cooking. Gas cooking can also release nitrogen dioxide and other combustion products.
Using an extractor hood that vents outdoors, where available, can reduce exposure.
Other combustion sources such as tobacco smoke, open fires, wood burners, candles and incense can also add particles and gases to indoor air.
People with sensitive airways may find that reducing these sources improves symptoms.
Cleaning products, sprays and fragrances
Some household products release volatile organic compounds (VOCs) or aerosols that can irritate sensitive airways.
Strong smells do not necessarily mean that something is dangerous, and an odour-free product is not automatically harmless. However, people with asthma or other reactive airway disease may notice symptoms after using sprays, aerosols, fragrances or strong cleaning products.
If a product repeatedly triggers coughing, wheezing or chest tightness, consider using a simpler non-spray alternative and ventilating the area appropriately.
NICE specifically advises people whose asthma is triggered by household sprays, air fresheners or aerosols to avoid them where possible and use non-spray alternatives.
Do air purifiers help?
Portable air cleaners fitted with an appropriate particle filter, commonly a HEPA filter, can reduce concentrations of airborne particles in a room.
They may be useful in some circumstances, particularly where outdoor particles or airborne allergens are a concern.
However, an air purifier has important limitations.
It cannot:
- repair a leak
- remove damp from a building
- prevent condensation caused by inadequate heating or ventilation
- remove mould growing inside walls or other building materials
- replace adequate kitchen or bathroom extraction
If there is an identifiable source of pollution, removing or controlling the source is usually more important than trying to filter the resulting pollution afterwards.
Should people with aspergillosis wear a mask outdoors?
Most people with aspergillosis do not need to wear a mask whenever they go outside.
However, respiratory protection may be sensible during activities that can generate unusually high concentrations of dust or fungal material, such as:
- handling compost
- turning compost heaps
- clearing large amounts of decaying vegetation
- working in very dusty environments
- entering buildings with extensive mould contamination
- some construction or renovation activities
The appropriate level of precaution depends on the individual's condition and immune status.
Avoiding air pollution should not mean avoiding life
It is possible to become understandably anxious about fungal spores, pollution and environmental exposure after being diagnosed with aspergillosis.
But trying to eliminate all exposure is impossible and can unnecessarily restrict daily life.
Outdoor activity, exercise, social contact and spending time in nature can all be important for physical and mental wellbeing.
A more useful approach is to identify high or avoidable exposures and reduce those, rather than treating ordinary air as dangerous.
Practical steps for cleaner air
- Keep your home dry and deal promptly with leaks and water damage.
- Use kitchen and bathroom extraction where available.
- Ventilate appropriately when cooking, showering or drying clothes.
- Avoid smoking and second-hand tobacco smoke.
- Reduce combustion sources such as candles and open fires if they aggravate symptoms.
- Use non-spray cleaning products if aerosols trigger your airways.
- Check outdoor air-quality information when pollution is high or when your breathing is unusually sensitive.
- Consider particle filtration where there is a clear reason for it, but do not use an air purifier as a substitute for fixing damp or pollution sources.
- Avoid unnecessarily high fungal exposure from activities such as handling mouldy material or disturbing compost.
- Continue normal activities when conditions are reasonable rather than attempting to avoid all environmental exposure.
When should I seek medical advice?
Environmental conditions can affect symptoms, but worsening breathlessness, wheezing, coughing or sputum should not automatically be attributed to air quality.
Contact your healthcare team if symptoms are persistent, significantly worse than usual or accompanied by other signs of illness.
People with asthma should follow their asthma action plan and seek urgent medical help for severe breathing difficulty or symptoms that are not responding to their usual treatment.
Further information
- Outdoor Air Pollution and Aspergillosis
- Reducing Aspergillus Exposure and Environmental Risk
- NICE: Indoor air quality at home
References
- National Institute for Health and Care Excellence (NICE). Indoor air quality at home (NG149). NICE guidance.
- Jiménez-Uribe DA, Acevedo-Barrios R, Rubiano-Labrador C, et al. Relationship of airborne fungal spores to epidemiological data on respiratory disease: a systematic review. Aerobiologia. 2026;42:11. Full article.
Audience: Patients, carers and non-specialist healthcare professionals
Last reviewed: 17 August 2026
New tools to diagnose allergic fungal rhinosinusitis: what has changed?
Updated August 2026
When this article was first published, researchers were investigating whether new combinations of tests could help diagnose allergic fungal rhinosinusitis (AFRS) — previously often called allergic fungal sinusitis (AFS) — without relying so heavily on findings obtained during sinus surgery.
That remains an important goal, but our understanding of AFRS has developed considerably.
What is allergic fungal rhinosinusitis?
AFRS is now generally regarded as a particular form of chronic rhinosinusitis with nasal polyps (CRSwNP). It involves a strong type 2 inflammatory response associated with fungi in the sinuses. A 2026 Grand Rounds review of AFRS describes it as a distinct, non-invasive endotype of chronic rhinosinusitis with nasal polyps.
The fungi are present in the thick, eosinophil-rich mucus within the sinuses but, importantly, AFRS is non-invasive: fungal hyphae do not normally invade healthy surrounding sinus tissue.
This distinguishes AFRS from invasive fungal sinusitis, which is a very different and potentially life-threatening condition.
Why has AFRS traditionally been difficult to diagnose?
For many years, diagnosis has commonly been based on the Bent and Kuhn criteria, developed in the 1990s.
These include:
- evidence of an immediate allergic response to fungi
- nasal polyps
- characteristic changes on CT scans
- thick, eosinophil-rich mucus without fungal invasion of tissue
- fungi demonstrated within material removed from the sinuses
The difficulty is that some of the strongest evidence may only become available after sinus surgery. A 2025 contemporary review of AFRS highlights this limitation and questions the specificity and practicality of the traditional diagnostic criteria.
This led researchers to investigate whether blood tests, allergy testing, imaging and other markers could identify AFRS more reliably before an operation.
What have we learned since?
Research has continued to show that blood tests, fungal-specific IgE, eosinophils, CT imaging and other measurements can all contribute useful information.
However, there is still no single blood test or biomarker that reliably diagnoses AFRS on its own. Diagnosis continues to depend on combining clinical history, allergy and immunological findings, imaging and, where available, examination of sinus material.
At the same time, researchers have begun questioning the traditional diagnostic criteria themselves. A major multidisciplinary AFRS workshop published in 2025 brought together experts from several disciplines to review diagnosis, management, associated conditions and disease mechanisms. The group concluded that improved diagnostic criteria and better biomarkers are important priorities for future research.
AFRS is increasingly understood as a complex inflammatory condition involving interactions between fungi, the immune system and probably genetic and environmental factors. Research into the underlying biology has identified abnormalities in fungal-driven inflammatory pathways and local antifungal immune responses. A 2023 review of developments in AFRS pathophysiology and treatment discusses these mechanisms in more detail.
Has improved diagnosis reduced the need for surgery?
This was one of the hopes behind the research discussed in the original version of this article, but the picture is now more nuanced.
Surgery remains an important part of treatment for many people with AFRS.
Endoscopic sinus surgery can remove accumulated eosinophilic mucus and fungal material, remove obstructing nasal polyps, reopen affected sinuses and allow topical treatments to reach the sinus cavities more effectively.
The 2025 contemporary review describes surgery followed by topical corticosteroids and saline irrigation as the mainstay of AFRS treatment. The 2026 Grand Rounds review similarly emphasises comprehensive endoscopic sinus surgery followed by long-term topical anti-inflammatory treatment.
Medical treatment after surgery is important because AFRS has a significant tendency to recur.
What about biologic treatments?
There is increasing interest in biologic medicines that target type 2 inflammation. Some of these treatments are already used for severe asthma and chronic rhinosinusitis with nasal polyps.
A 2025 systematic review and meta-analysis of biologics in AFRS found encouraging improvements in symptoms and measures of disease activity, although the available studies were relatively small and varied considerably.
A further 2025 systematic review and meta-analysis of biologics in difficult-to-treat AFRS also found evidence of short-term benefit.
These treatments may therefore become increasingly important for selected people with recurrent or difficult-to-control AFRS, but more evidence is needed to establish exactly who benefits, when biologics should be introduced and how they fit alongside surgery and other treatments.
Why better diagnosis still matters
The objective is therefore not simply to develop a test that allows patients to avoid surgery.
Better diagnostic tools could help doctors:
- recognise AFRS earlier
- distinguish it from other forms of chronic rhinosinusitis
- identify people who need specialist assessment
- select the most appropriate treatment
- monitor disease and recurrence
- better understand which patients might benefit from newer treatments
The research described in the original article was part of an important change in thinking. Rather than viewing AFRS simply as fungal material that needs to be removed from the sinuses, we now understand it as a complex inflammatory disease associated with fungi.
Our ability to diagnose, classify and treat AFRS continues to evolve.
For a fuller explanation of fungal rhinosinusitis, its symptoms, diagnosis and treatment, see our Fungal Rhinosinusitis information page.